ZYZexin Yang

Zexin Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zexin Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Chengcheng Yang

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Jie Xu

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Junqi Zhang

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Min Gu

    Department of Urology, the Second Affiliated Hospital of Nanjing Medical University

    1 shared publication
  • Min Gu

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication
  • Ming Zheng

    Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

    1 shared publication

Latest Publications

  • Open Access

    Iguratimod Modulates M1 Macrophage Polarization Via the NOTCH4–KLF4 Axis to Alleviate Antibody-Mediated Rejection

    by Zhou Hang, Junqi Zhang, Chengcheng Yang, Ming Zheng, Zexin Yang, Jie Xu, Peng Han, Min Gu

    Background: Iguratimod (IGT) is a small-molecule anti-inflammatory agent that effectively attenuates the progression of antibody-mediated rejection (ABMR). However, the underlying mechanism of action of IGT remains poorly understood. Thus, this study aimed to investigate the mechanism through which IGT regulates macrophage polarization and ABMR. Methods: A mouse model of ABMR was established by performing kidney transplantation after skin graft-induced sensitization. Experimental interventions included neurogenic locus notch homolog protein 4 (NOTCH4) knockout mice and oral administration of IGT. RNA sequencing, quantitative polymerase chain reaction, Western blotting (WB), flow cytometry, and immunofluorescence (IF) staining were performed to investigate M1 macrophage polarization and the Jagged1–NOTCH4 signaling pathway. Results: This study found that IGT significantly reduced M1 macrophage infiltration into renal allografts in a mouse model of ABMR. Transcriptomic sequencing and subsequent biological experiments indicated that IGT may regulate macrophage polarization through the Jagged1–NOTCH4 pathway. Conclusion: M1 macrophage polarization may contribute to the initiation and progression of ABMR following kidney transplantation. IGT attenuates M1 macrophage polarization by inhibiting Jagged1–NOTCH4–Krüppel-like Factor 4 (KLF4) signaling.

  • Open Access

    Role of Scar‐Associated Macrophages in Organ Fibrosis Diseases

    by Runmin Ding, Zexin Yang, Yuxi Chen, Qiqin Yu, Yisheng Ji, Zijie Wang, Min Gu

    Fibrosis refers to the scarring and hardening of tissue resulting from the excessive deposition of extracellular matrix (ECM) proteins by myofibroblasts during chronic inflammatory responses, which can ultimately lead to organ failure and potentially death. Different states of macrophage activation are critical in regulating both the progression and regression of fibrosis. However, the conventional M1/M2 polarization model fails to accurately capture the dynamic and heterogeneous states of macrophages observed in vivo. As a result, an increasing number of studies have begun to classify macrophages based on their functional phenotypes. One specific subset of functionally distinct macrophages, termed scar‐associated macrophages (SAMs), has been confirmed to play a significant regulatory role in organ fibrosis. This review provides a comprehensive summary of recent advances in understanding the role of SAMs in fibrotic diseases across multiple organs, including the liver, lungs, heart, and kidneys. It further explores the emerging conceptual framework of hot and cold fibrosis, highlighting the potential role of SAMs as central cellular mediators that sustain a positive feedback loop between inflammation and fibrosis in the “hot fibrosis” state. Building on these insights, this review also discusses future research directions aimed at developing targeted therapeutic strategies to modulate SAM activity and mitigate fibrosis in diverse organ systems.